BioPharma Resources

Drug Trial Radar · NCT01950819

Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)

A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation

Last checked: Nov 19, 2026Latest source record: Jan 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,037 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,037

Actual

Start

Dec 3, 2013

Primary completion

Feb 1, 2017

Study completion Jan 17, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-year, randomized, multicenter, open-label, 2-arm study evaluating the graft function of everolimus and reduced CNI versus MPA and standard CNI in adult de novo renal transplant recipients.

Conditions

  • End Stage Renal Disease (ESRD)
  • Chronic Kidney Disease (CKD)
  • Hemodialysis
  • Renal Replacement Therapy
  • Renal Transplantation

Interventions

  • Induction therapyBiological

    All subjects received induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.

  • CorticosteroidsDrug

    All subjects received maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day was maintained.

  • EVR+rCNIDrug

    Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)

  • MPA+sCNIDrug

    Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Failure on the Composite of Treated Biopsy-proven Acute Rejection (tBPAR) or Estimated Glomerular Filtration Rate (eGFR) < 50 mL/Min/1.73m2.Time frame: Month 12 is Primary, Month 24 secondary

Locations

184 sites in 42 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Loma Linda, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    San Diego, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Burlington, Massachusetts

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Livingston, New Jersey

  • Novartis Investigative Site

    Buffalo, New York

  • Novartis Investigative Site

    The Bronx, New York

  • Novartis Investigative Site

    Chapel Hill, North Carolina

  • Novartis Investigative Site

    Durham, North Carolina

  • Novartis Investigative Site

    Winston-Salem, North Carolina

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Harrisburg, Pennsylvania

  • Novartis Investigative Site

    Providence, Rhode Island

  • Novartis Investigative Site

    Charleston, South Carolina

  • Novartis Investigative Site

    Nashville, Tennessee

  • Novartis Investigative Site

    Dallas, Texas

  • Novartis Investigative Site

    Fort Worth, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Salt Lake City, Utah

  • Novartis Investigative Site

    Charlottesville, Virginia

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Madison, Wisconsin

  • Novartis Investigative Site

    Milwaukee, Wisconsin

Showing 40 of 184 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.